Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy

Abstract Introduction Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR...

Full description

Bibliographic Details
Main Authors: Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M. Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H. Sheikh
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-03-01
Series:Cardiology and Therapy
Subjects:
ATTR amyloidosis
ATTR cardiomyopathy
ATTR polyneuropathy
Real-world
Tafamidis
Online Access:https://doi.org/10.1007/s40119-024-00362-9

Internet

https://doi.org/10.1007/s40119-024-00362-9

Similar Items